Pharmacokinetics and residues of ciprofloxacin and its metabolites in broiler chickens

Research in Veterinary Science

Volumn 71, Issue 2, 2001, Pages 101-109

  Anadon A ^a   Martinez Larranaga M R ^a   Iturbe, J ^a   Martinez M A ^a   Diaz M J ^a   Frejo, M T ^a   Martinez M ^a  

^a Instituto Nacional de Toxicologia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

7 (2 AMINOETHYLAMINO) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; DRUG METABOLITE; DRUG RESIDUE; OXOCIPROFLOXACIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHICKEN; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; KIDNEY PARENCHYMA; LIVER; MALE; MUSCLE TISSUE; NONHUMAN; SKIN;

GALLUS GALLUS;

EID: 0035189149     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1053/rvsc.2001.0494     Document Type: Article

References (56)

1. Pharmacology and Toxicology of Quinolones
2. Pharmacokinetics and residues of enrofloxacin in chickens
3. Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs
4. Pharmacokinetics of ciprofloxacin following intravenous and oral administration in broiler chickens
5. Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits
6. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid
7. Metabolism of ciprofloxacin in man
8. Pharmacokinetics of ciprofloxacin: Intravenous and increasing oral doses
9. Renal elimination of sulfociprofloxacin, a new metabolite of ciprofloxacin
10. Ciprofloxacin, a quinoline carboxylic acid compound active against aerobic and anaerobic bacteria
11. DNA gyrase and the supercoiling of DNA
12. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens
13. Pharmacokinetics of ciprofloxacin in ponies
14. Absolute oral bioavailability of ciprofloxacin
15. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
16. In vitro activity of ciprofloxacin (Bay 09867)
17. Intramuscular and oral disposition of enrofloxacin in African grey parrots following single and multiple doses
18. Multiple dose pharmacokinetics of ciprofloxacin and two of its metabolites as determined in normal volunteers
19. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
20. Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in chickens
21. DNA topoisomerases
22. In vitro evaluation of various quinolone antibacterial agents against veterinary mycoplasmas and porcine respiratory bacterial pathogens
23. Pharmacokinetics of ciprofloxacin after oral and parenteral administration
24. Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows
25. Liquid chromatographic analysis of ciprofloxacin and ciprofloxacin metabolites in body fluids
26. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs
27. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection
28. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections
29. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and intramuscular administration in sheep
30. Comparative pharmacokinetic parameters of new systemic fluoroquinolones
31. Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs
32. Hepatobiliary kinetics and excretion of ciprofloxacin
33. Quinolone resistance in clinical practice: Occurrence and importance
34. In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin
35. In vitro susceptibility of avian Escherichia coli and Pasteurella multocida to danofloxacin and five other antimicrobials
36. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time
37. Correlation of pharmacokinetic parameters to efficacy of antibiotics: Relationship between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia
38. Pharmacodynamics of the fluoroquinolones
39. Estimating the dimension of a model
40. ELSFIT A Program for the extended least squares fit to individual pharmacokinetic data
41. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: The target of the drugs is DNA
42. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA
43. Pharmacokinetics of ciprofloxacin
44. Transfer of ciprofloxacin to bile and determination of biliary metabolites in humans
45. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives
46. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data
47. Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs
48. In vitro activity of premafloxacin a new extended-spectrum fluoroquinolone, against pathogens of veterinary importance
49. In vitro activity of Bay 09867, a new quinolone derivative, compared with those of other antimicrobial agents
50. Tissue penetration and metabolism of ciprofloxacin
51. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations
52. Ciprofloxacin in horses: Antimicrobial activity, protein binding and pharmacokinetics
53. Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay